Premium
ATTEMPTED SUICIDE AND ALCOHOLISM
Author(s) -
Koller K. M.,
Castanos J. N.
Publication year - 1968
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1968.tb83231.x
Subject(s) - george (robot) , citation , psychology , medicine , psychiatry , psychoanalysis , library science , art , art history , computer science
The incidence of side effects in this study was 15%, but symptoms were of minor degree and did not necessitate discontinuance of the drug. The nature of the symptoms was identical with those reported by Spence (1966), and thus substantiate their association with fenfluramine. It is difficult to reconcile the apparent excitatory effect of the drug reported by those subjects with sleeplessness and those subjects who complained of tiredness. In essence, this drug appears to be free of the general stimulatory effects of many other anorectic drugs. There were no complaints attributable to tachycardia, tremor or extreme nervousness. Thus, this study supports the previous reports of the effectiveness of f-enfiuramine, and indicates that this is a clinically safe and well-tolerated drug. There appears to be some individuality in patient response, as despite appetite suppression, no significant weight loss occurred in eight of 22 subjects during a six-week course of the drug, suggesting that its effect upon appetite is moderate in some subjects. SUMMARY Fenfluramine has been studied and found to be an effective anorectic drug, producing sustained moderate weight loss after a ten-week course without dietary restriction. However, a number of patients sustained side effects, but none of these was so severe that the drug had to be discontinued.